

**Investment Objective**

The investment objective of the Kieger UCITS Fund - Kieger Impact Healthcare Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals. The fund is actively managed by the Investment Manager.

**SFDR classification: Article 9**

The fund has sustainable investment as its objective.

**Key Information**

**General Information**

ISIN	LU2488093456
BLOOMBERG	KGIHAAE LX
Fund Inception	01/10/2020
Share Class Inception	05/07/2023
Total Assets	USD 85.7m
Fund Currency	USD
Domicile	Luxembourg
Regulatory Status	SICAV
Legal Structure	UCITS
Dealing Frequency	Daily (CET 12pm)
Settlement	T+2
Distribution Policy	Accumulating

**Service Providers**

Management Company	FundRock Management Co. SA
Investment Manager	Kieger AG
Custodian Bank/ Administrator	Northern Trust Global Services SE
Auditor	Ernst & Young SA

**Fund Management**

Urban Fritsche (Lead Mgr)
Maria Specogna (Co-Mgr)
Raphael Oesch (Co-Mgr)

**Portfolio Statistics (3-Year Annualised)**

	Fund
Volatility	23.17%
Sharpe Ratio	-0.67
Tracking Error	-
Information Ratio	-
Beta	1.38
Active Share	94.07%

**Largest Holdings (%)**

BioNTech SE	3.9%
Radnet Inc	3.4%
Inspire Medical Systems Inc	3.4%
Natera Inc	3.4%
Revvity Inc	3.4%
Ambu A/S	3.4%
Amplifon Spa	3.3%
ResMed Inc	3.3%
Ionis Pharmaceuticals	3.2%
Hikma Pharmaceuticals PLC	3.2%
<b>Total Top 10 - out of 47</b>	<b>33.9%</b>

**Performance (%)**

Performance data are net of management fees, but do not reflect sales charges or the effect of taxes.



Past performance is no indication of current or future performance.

	1 Month	3 Months	YTD	1 Yr	3 Yrs	5 Yrs
EUR B Class Accumulating	-1.49%	0.31%	-4.02%	1.74%	-	-




**Market review:** After enjoying quite a run of outperformance, the Healthcare sector came under pressure in September. The main macro event of the month was the large US Fed rate cut, which buoyed growth sectors at the expense of the more defensive corners of the market. This dynamic was also present within the healthcare sector, with Medtech outperforming Pharma. Overall, we see this as a temporary setback as markets adjust to a new interest rate trajectory, as well as a testament to sector's strong YTD performance in the form of profit-taking. Two major oncology conferences took place this month; World Lung in San Diego and ESMO in Barcelona. The star of the show at World Lung was Summit and Akeso's PD1xVEGF antibody. Its results in advanced NSCLC were better than the current standard of care, which has not been improved in over 8 years. While there are many caveats to this data, such as the lack of diversity of the patient population, this may be the beginning of a new era in immuno-oncology. The European Association for the Study of Diabetes (EASD) conference in Madrid was highly awaited and widely attend following the large strides made in the understanding and treatment of diabetes, obesity, and associated diseases in the past few years. New obesity drugs such as those in the incretin class (e.g. GLP-1), represent the start of a broader wave of development. However, their mechanisms of action, along with their added benefits and potential side-effects, are not yet fully understood

**Portfolio changes:** No new position was initiated and we exited Guardant.


**Performance review:** The largest contributors were BioNTech (+108 bps / Summit Therapeutics and Akeso's PD1xVEGF presented results in advanced NSCLC that were better than the current standard of care. BioNTech rose in sympathy to Summit, as they are working on a similar drug together with Biotheus), Inspire Medical (+51 bps / very upbeat tone (strong patient demand, GLP-1 tailwind, confirmation of 2024 guidance, affirmatively saying that 2025 consensus was not unreasonable). Apple's announcement of having sleep apnea alert on Watch Series 10 also helped the stock) and Teladoc (+49 bps / broker note stating that Betterhelp should beat Q3 consensus, driven by web traffic that turned positive in July/August after 12 consecutive months of YoY declines). The largest detractors were Ionis (-53 bps / Announcement of USD 500mn stock offering), Organon (-43 bps / The stock was downgraded by a major broker. Later, Organon's announcement to buy Dermavant Sciences from Roivant for USD 1.2bn was not well received by the market) and Aspen (-43 bps / Stock sold-off after reported sales were lower than expected).

**ESG:** Firms in the portfolio did not report any material ESG issues in September.


**Regional Exposure (%)**



**Sector Exposure (%)**




**Market Cap Breakdown (%)**



Large = >15bn, Mid = 5-15bn, Small = <5bn

**Impact Theme Allocation (%)**



**Share Class Information**

Share Class	ISIN	Bloomberg	Investment Management Fee	TER - as of Dec 2023	Minimum Investment	NAV
USD A Class Accumulating	LU2207278073	KGIHAAUA LX	1.00%	1.21%	500,000	84.59
CHF A (H) Class Acc	LU2207278404	KGIHAHC LX	1.00%	1.27%	500,000	87.4
USD B Class Accumulating	LU2488093613	KGIHAAU LX	1.00%	1.22%	5,000	96.72
EUR B Class Accumulating	LU2488093456	KGIHAAE LX	1.00%	1.22%	5,000	92.56
CHF B Class Accumulating	LU2488093530	KGIHAAC LX	1.00%	1.22%	5,000	88.77
USD R Class Accumulating	LU2207278669	KGIHRUA LX	2.00%	2.22%	2,000	93.85

**Disclaimer**

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus.

A summary of the investor rights is available in English at

<https://kieger.com/regulatory-disclosures>. Further information about the sustainability-related aspects of the Fund is available at

<https://kieger.com/regulatory-disclosures>. The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

**Information for Swiss Investors:**

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

**Information for German Investors:**

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Line-Eid-Strasse 6, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email [facilityagent@acolin.com](mailto:facilityagent@acolin.com), or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

**Information for Austrian Investors:** The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email [foreignfunds0540@erstebank.at](mailto:foreignfunds0540@erstebank.at)

**Marketing in the European Union:**

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II") as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his home country Luxembourg. Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be copied or used for other purposes, nor may the content of the document be forwarded to third parties.